Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis
The causal role of neutrophil serine proteases in the pathogenesis of bronchiectasis was studied with brensocatib, an inhibitor of protease activation. Brensocatib therapy resulted in a longer time to the first bronchiectasis exacerbation than placebo.
Gespeichert in:
Veröffentlicht in: | The New England journal of medicine 2020-11, Vol.383 (22), p.2127-2137 |
---|---|
Hauptverfasser: | , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The causal role of neutrophil serine proteases in the pathogenesis of bronchiectasis was studied with brensocatib, an inhibitor of protease activation. Brensocatib therapy resulted in a longer time to the first bronchiectasis exacerbation than placebo. |
---|---|
ISSN: | 0028-4793 1533-4406 |
DOI: | 10.1056/NEJMoa2021713 |